Over
the projected period, an increasing number of product launches related to
anti-microbial medicines is anticipated to fuel the growth of the worldwide
cell expansion market. For instance, in October 2022, Merck, a pioneer in
research and technology around the world, introduced a new VirusExpress
Lentiviral Production Platform based on its expertise as a company that
performs contract research, development, and manufacture. By overcoming
production barriers for lentiviral vectors, this novel platform can reduce
process development time by about 40%. By streamlining the upstream procedure,
Merck's VirusExpress Platform makes cell and gene therapy development simpler
to control, modify, and scale.
The
global cell expansion market is anticipated to increase over the duration of
the projected period as a result of market participants increasing their
investments in biotechnology goods linked to cell and gene therapy. For
instant, February 2022, the life sciences strategic investment fund has been
launched by the global corporation FUJIFILM Corporation, based in Japan. It
will be managed by the Life Sciences Corporate Venture Capital (LS-CVC), a
recently formed entity under Fujifilm's Life Sciences Strategy Headquarters in
Tokyo. Fujifilm will invest US$54 million internationally, with an emphasis on
cutting-edge biotechnology through collaborations with startup businesses. The
company's existing life science investment portfolio, which comprised
investments in regenerative medicine, cell treatments, and drug development
research goods, will also be managed by the LS-CVC in addition to managing this
new fund.
The
development of specialised stem cell manufacturing and expansion facilities is
anticipated to fuel the worldwide cell expansion market over the course of the
forecast period. For instance, April 2022, Cellistic, an iPSC cell therapy
CDMO, was introduced by Ncardia, a pioneer in contract research, development,
and manufacture of induced pluripotent stem cell (iPSC)-based solutions
(Contract Development and Manufacturing Organization). The creation and
manufacture of human iPSC-based cell therapies is the primary focus of
Cellistic. Innovative cell therapy developers wanting to market cutting-edge
therapeutics will find Celletic to be an excellent partner because to its
knowledge and focus on iPSC reprogramming, differentiation, and expansion
protocols. However, the ethical issues surrounding the use of cell expansion to
develop new research results and clinical experimentation are a particular
hindrance to the advancement of the market. Other constraints on the growth of
the cell expansion market include the need for a skilled workforce and
high-tech instrumentation.
Due
to an increase in product launches in the region, North America is anticipated
to have a leading position in the global cell expansion market over the
forecast period. For instance, in July 2020, the Corning X-SERIES cell
processing platform has been introduced, according to Corning Incorporated, a
global technological business with headquarters in the United States. Using the
platform, human blood and blood products can be processed quickly, sterilely,
automatically, and efficiently to produce pure immune cell populations for cell
and gene therapy applications.
Cell
expansion market are expected to generate the biggest revenue share in
North America during the forecasted period. The substantial market
share of this industry is primarily explained by the increasing cancer
incidence, increasing government funding, increasing stem cell therapy research
activities, growing public awareness of cutting-edge treatment options,
increasing geriatric population, and the substantial presence of industry
players in the region. Moreover, in the upcoming years, the region will
continue to hold the top spot because to increasing government funding
initiatives that have sped up the production of stem cells and the development
of regenerative medicine and cellular therapy products. This in turn increases
the demand for cell expansion platforms in this region. For instance, The FDA
and the Medical Technology Enterprise Consortium (MTEC) provided USD 5.3
million in funding to the Southwest Research Institute (SwRI) in October 2019.
(US). These funds were employed by the SwRI to propagate cells for the
development of customised regenerative medicine. The ability of the area to
produce income is improved by these investments.
The
Asia Pacific cell expansion market is anticipated to experience fastest revenue
growth throughout the forecast period. Due to increased efforts made by
numerous local pharmaceutical and biotechnology companies to develop and market
their cellular therapies. Additionally, Asia Pacific will expand at the rapid
speed throughout the projection period and offer attractive opportunities for
major participants in the cell expansion technologies market due to its quick
economic development and low operating costs.
Some of the prominent players in the global cell expansion market include, Beckman Coulter, Inc, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc., Becton, Dickinson and Company, Terumo BCT, Inc., Takara Bio, Inc., Corning, Inc., Stemcell Technologies, Inc., GE Healthcare, Merck KGaA (Sigma-Aldrich Co. LLC), Lonza, Miltenyi Biotec, Octane Biotech, Inc., Corning Incorporated, Eppendorf AG, and Lonza Group.
Reach Us
